# US 2014/0350380 A1 · Identification and uses of brain activity networks

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0350380 A1
- Document ID: US20140350380A1
- Status: Published application
- Kind: A1
- Application number: 14/345,331
- Filed: 2012-09-18
- Published: 2014-11-27
- Earliest claimed: 2011-09-19
- Assignees: The Feinstein Institute for Medical Research
- Applicants: The Feinstein Institute for Medical Research
- Inventors: David Eidelberg
- Web page: https://patentgrep.com/patent/US20140350380A1

## CPC

- G06T 7/0012: {Biomedical image inspection}
- A61B 5/0042: {for the brain}
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61B 5/4082: {Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette}
- A61B 5/4848: {Monitoring or testing the effects of treatment, e.g. of medication}
- A61B 6/037: {Emission tomography}
- A61B 6/501: {for diagnosis of the head, e.g. neuroimaging or craniography}
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G06T 2207/10088: Magnetic resonance imaging [MRI]
- G06T 2207/10104: Positron emission tomography [PET]
- G06T 2207/30016: Brain
- G06T: IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Methods for identifying networks correlating with placebo effects, progression of neurological disease symptoms, progression of pre-phenoconversion states of neurological diseases, and efficacious/non-efficacious candidate treatments for neurological diseases are provided.

## Claims

### Claim 1

A method for identifying a pattern of brain activity associated with a placebo effect response to a placebo treatment for a disease or disorder comprising:
determining, by positron emission tomography (PET) or magnetic resonance imaging (MRI) in a subject receiving, or who has received, the placebo treatment for the disease or disorder, functional activity at each of a plurality of coordinates of the subject's brain during at least two different time points and identifying, through spatial co-variance analysis of the functional activity, which coordinates show a consistent trend over the at least two different time points in functional activity correlating with a placebo effect response to the placebo treatment,
so as to thereby determine a pattern of brain activity associated with a placebo effect response to a placebo treatment for a disease or disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease or disorder is a neurological disease or disorder.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein an improvement in the disease or disorder is determined by the subject exhibiting an improvement in at least one symptom of the disease or disorder or an improvement in at least one measurable parameter associated with the disease or disorder.

### Claim 7 (depends on 1)

The method of claim 1, wherein the efficacious treatment for the disease or disorder improves at least one symptom of the disease or disorder or one measurable physical parameter associated with the disease or disorder.

### Claim 8 (depends on 1)

The method of claim 1, wherein the functional activities are, or have been, determined as showing a consistent trend over at least three different time points.

### Claim 9 (depends on 1)

The method of claim 1, wherein the consistent trend is a monotonic ordinal trend.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the coordinates are three-dimensional coordinates.

### Claim at position 10

12-16. (canceled)

### Claim 17 (depends on 1)

The method of claim 1, further comprising determining the efficacy of a test treatment for the disease or disorder on one or more subjects by assessing if an improvement occurs in one or more symptoms of, or measurable parameter of, the disease or disorder during or subsequent to administration of the test treatment to the subject, wherein an improvement in not exhibiting the pattern of brain activity associated with a placebo effect can be attributed to the test treatment.

### Claim 18

(canceled)

### Claim 19

A method for determining efficacy of a candidate treatment, administered to a subject having a brain disorder, on a rate of progression of the brain disorder comprising:
a) determining, by positron emission tomography (PET) or magnetic resonance imaging (MRI) during administration of or after administration of the candidate treatment to the subject, functional activity at each of a plurality of predetermined coordinates of the subject's brain so as to determine a first pattern of activity, which coordinates have previously been identified through spatial co-variance analysis of functional activity as determined by PET or MRI in the brain of the subject or in the brain(s) of one or more other subjects suffering from the brain disorder during at least two different time points while the subject was, or subjects were, exhibiting the symptom or brain disorder as showing a consistent trend in functional activity which correlates with worsening of the brain disorder; and
b) comparing the first pattern of activity determined in step a) with a previously determined baseline pattern of activity,
wherein an expression of the first pattern of activity lower than the previously determined baseline pattern of activity indicates that the candidate treatment is efficacious in reducing the rate of progression of the brain disorder, and wherein an expression of the first pattern of activity higher than the previously determined baseline pattern of activity indicates that the candidate treatment is not efficacious in reducing the rate of progression of the brain disorder.

### Claim 20 (depends on 19)

The method of claim 19, wherein the baseline pattern of activity is determined through identifying a plurality of coordinates through spatial co-variance analysis of functional activity, as quantified by PET or MRI in the brain of the subject or in the brain(s) of one or more other subjects suffering from the brain disorder during at least two different time points while the subject was, or subjects were, exhibiting the symptom or brain disorder, which coordinates show a consistent trend in functional activity which correlates with worsening of the brain disorder.

### Claim 21

(canceled)

### Claim 22

A method for identifying a pattern of brain activity specifically associated with a symptom of a brain disorder comprising:
determining, by positron emission tomography (PET) or functional magnetic resonance imaging (MRI) in a subject exhibiting the symptom, functional activity at each of a plurality of coordinates of the subject's brain during at least two different time points and identifying, through spatial co-variance analysis of the functional activity, which coordinates show a consistent trend over the at least two different time points in functional activity correlating with the symptom,
so as to determine a baseline pattern of activity specifically associated with the symptom of the brain disorder.

### Claim 23

(canceled)

### Claim 24

A method for identifying a pattern of brain activity specifically associated with efficacious treatment of a symptom of a brain disorder comprising:
determining, by positron emission tomography (PET) or magnetic resonance imaging (MRI) in a subject exhibiting the symptom and being treated with a treatment efficacious for that symptom, functional activity at each of a plurality of coordinates of the subject's brain during at least two different time points and identifying, through spatial co-variance analysis of the functional activity, which coordinates show a consistent trend over the at least two different time points in functional activity correlating with efficacious treatment of the symptom, so as to thereby determine a baseline pattern of activity specifically associated with efficacious treatment of the symptom of the brain disorder.

### Claim 25

A method for identifying a pattern of brain activity specifically associated with a pre-phenoconversion rate change of a neurological disease comprising:
determining, by positron emission tomography (PET) or magnetic resonance imaging (MRI) in a subject in a pre-phenoconversion state, functional activity at each of a plurality of coordinates of the subject's brain during at least two different time points and identifying, through spatial co-variance analysis of the functional activity, which coordinates show a consistent trend in functional activity over the at least two different time points correlating with the pre-phenoconversion rate,
so as to thereby determine a pattern of brain activity specifically associated with the pre-phenoconversion rate change of the neurological disease.

### Claim at position 20

26-58. (canceled)

### Claim 59 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 60

(canceled)

### Claim 61 (depends on 59)

The method of claim 59, wherein is a mammal is a human.

### Claim 62

(canceled)

### Claim 63

(canceled)

### Claim 64 (depends on 1)

A computer-readable medium comprising instructions stored thereon which, when executed by a data processing apparatus, causes the data processing apparatus to perform a method of claim 1.

### Claim 65 (depends on 1)

A system comprising:
one or more data processing apparatus; and
a computer-readable medium coupled to the one or more data processing apparatus having instructions stored thereon which, when executed by the one or more data processing apparatus, cause one or more data processing apparatus to perform a method of claim 1.
